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The  Brighton  Collaboration  Viral  Vector  Vaccines  Safety  Working  Group  (V3SWG)  was  formed  to evaluate
the  safety  of  live,  recombinant  viral  vaccines  incorporating  genes  from  heterologous  viruses  inserted  into
the  backbone  of  another  virus  (so-called  “chimeric  virus  vaccines”).  Many  viral  vector  vaccines  are  in
advanced  clinical  trials.  The ﬁrst  such  vaccine  to be approved  for marketing  (to  date  in  Australia,  Thailand,
Malaysia,  and  the Philippines)  is  a vaccine  against  the  ﬂavivirus,  Japanese  encephalitis  (JE), which  employs
a  licensed  vaccine  (yellow  fever  17D)  as  a vector.  In this  vaccine,  two  envelope  proteins  (prM-E)  of YF
17D  virus  were  exchanged  for the  corresponding  genes  of  JE  virus,  with  additional  attenuating  mutations
incorporated  into  the  JE  gene  inserts.  Similar  vaccines  have  been  constructed  by  inserting  prM-E  genes
of  dengue  and  West  Nile  into  YF 17D  virus  and  are  in  late  stage  clinical  studies.  The  dengue  vaccine  is,
however,  more  complex  in  that  it requires  a mixture  of  four  live  vectors  each  expressing  one  of  the  four
dengue  serotypes.  This  vaccine  has been  evaluated  in multiple  clinical  trials.  No  signiﬁcant  safety  concerns
have  been  found.  The  Phase  3 trials  met  their  endpoints  in terms  of overall  reduction  of  conﬁrmed  dengue
fever,  and,  most  importantly  a  signiﬁcant  reduction  in severe  dengue  and  hospitalization  due  to dengue.
However,  based  on  results  that  have  been  published  so  far, efﬁcacy  in  preventing  serotype  2 infection  is
less  than  that for the  other  three  serotypes.  In  the  development  of  these  chimeric  vaccines,  an important
series  of comparative  studies  of safety  and  efﬁcacy  were  made  using  the  parental  YF  17D  vaccine  virus
as  a benchmark.  In  this  paper,  we  use a  standardized  template  describing  the  key  characteristics  of  the
novel  ﬂavivirus  vaccine  vectors,  in  comparison  to  the parental  YF 17D  vaccine.  The  template  facilitates
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scientiﬁc  discourse  among  key  stakeholders  by increasing  the  transparency  and  comparability  of  infor-
mation. The  Brighton  Collaboration  V3SWG  template  may  also  be useful  as a guide  to  the  evaluation  of
other recombinant  viral vector  vaccines.
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. Preamble
.1. Need for working group and development of a standardized
emplate for collection of key information for risk/beneﬁt
ssessment of viral vector vaccines
Recombinant viral vectors provide an effective means for het-
rologous antigen expression in vivo and thus represent promising
latforms for developing novel vaccines against human pathogens
uch as Ebola, human immunodeﬁciency virus (HIV), tuberculo-
is, and malaria) [1–9]. Preclinical evaluation of such viral vector
accines has indicated their potential for immunization and an
ncreasing number of candidate vaccines are entering human clini-
al trials. Improving our ability to anticipate potential safety issues
nd meaningfully assess or interpret safety data from trials of such
ew viral vector vaccines will increase the likelihood of public
cceptance should they be licensed [10–13].
The Brighton Collaboration (www.brightoncollaboration.org)
as  formed in 2000 as an international voluntary collaboration to
nhance the science of vaccine safety research [e.g., via develop-
ent of standardized case deﬁnitions of adverse events following
mmunizations (AEFI)] [14]. In recognition of these needs in this
omain, the Brighton Collaboration created the Viral Vector Vac-
ines Safety Working Group (V3SWG) in October 2008. Analogous
o the value embodied in standardized case deﬁnitions for AEFI,
he V3SWG believes a standardized template describing the key
haracteristics of a novel vaccine vector, when completed and
aintained with the latest research, will facilitate scientiﬁc dis-
ourse among key stakeholders by increasing the transparency and
omparability of information. Fortunately, the International AIDS
accine Initiative (IAVI) had already developed an internal tool
o assess the risk/beneﬁt of different viral vectors under its spon-
orship. The IAVI graciously shared this tool with the V3SWG for
daptation and broader use as a standardized template for col-
ection of key information for risk/beneﬁt assessment on any viral
ector vaccine. This tool was aimed at identifying potential major
urdles or concerns that would need to be addressed during the
evelopment of a vectored vaccine. The template collects informa-
ion on the characteristics of the wild type virus from which the
ector was derived as well as known effects of the proposed vaccine
ector in animals and humans, manufacturing features, toxicology
nd potency, nonclinical studies, and human use, with an overall
dverse effect and risk assessment.
The V3SWG hopes that eventually all developers/researchers of
iral vector vaccines (especially those likely to be used in humans
n the near future) will complete this template and submit it to the
3SWG and Brighton Collaboration for peer review and eventual
ublication in Vaccine. Following this, to promote transparency,
he template will be posted and maintained on the Brighton
ollaboration website for use/reference by various stakeholders.
urthermore, recognizing the rapid pace of new scientiﬁc develop-
ents in this domain (relative to AEFI case deﬁnitions), we  hope to
aintain these completed templates “wiki-” style with the help of
righton Collaboration and each vector vaccine “community.”
.2. Need for risk/beneﬁt assessment of live virus vaccines based
pon  a yellow fever vaccine backbone
Yellow fever (YF) is a mosquito-borne ﬂavivirus disease that
s has long endangered persons in sub-Saharan Africa andtd.
tropical  areas in South America and is associated with a case fatality
rate of 20-50% [15]. Since no effective anti-yellow fever virus med-
ications are available and current mosquito-control measures are
inadequate, vaccination remains paramount to YF prevention and
control. Although appropriately controlled efﬁcacy studies have
never been carried out, the decline in YF cases following vaccina-
tion campaigns and the production in most studies of neutralizing
antibodies in more than 95% of vaccinees are considered sufﬁ-
cient evidence that the 17D vaccine is effective. Regulations call for
the vaccine to be administered every ten years; however, a recent
recommendation by WHO’s Strategic Advisory Group is that the
vaccine need only be given once [16].
The live, attenuated YF 17D vaccine was  previously deemed to
be the world’s safest and a model for the development of other live
virus vaccines including polio, measles, mumps  and varicella. Con-
sequently, live vaccines against other ﬂaviviruses, such as Japanese
encephalitis virus, West Nile virus, and the four serotypes of dengue
viruses, based on the YF 17D virus vaccine began to be devel-
oped. In 2001, however, severe rare reactions that were frequently
fatal became recognized [17–19]. These reactions involved multi-
ple organ systems and were named yellow fever vaccine-associated
viscerotropic disease (YEL-AVD). As a consequence, in addition to
live virus vaccines, inactivated vaccines, including one for YF, are
being developed.
Risk  groups for the development of YEL-AVD include elderly
males as young as 56 years [20], women  in their prime child-bearing
years [21], and persons thymectomized as treatment for thymoma
[22]. Guidelines for the deﬁnition of viscerotropic disease and for
the association of YF vaccine with viscerotropic disease have been
developed by a Brighton Collaboration working group [23]. In addi-
tion to YEL-AVD, other rare vaccine reactions include anaphylaxis
and neurological disease called YF vaccine-associated neurological
disease (YEL-AND). These reactions are rarely fatal or result in long
term sequelae. Recognition of YEL-AVD has had a number of conse-
quences including changes in recommendations for the vaccination
of prospective travelers to and inhabitants in jungle (sylvatic) or
savanna (intermediate) regions where they have a risk of exposure
to YF virus-infected mosquitoes.
The feared complication of YF is spread of the virus to urban
areas where the principal mosquito vector is Aedes aegypti, a
mosquito that has become difﬁcult if not impossible to eradicate
in areas of huge tropical and subtropical municipalities with their
large urban slums. Strategies for vaccination have also become
complex as the number of cases of YEL-AVD in travelers have
exceeded the number of cases of YF [15]. In South America, during
periods of low virus activity, the risk to travelers of serious adverse
events from the vaccine, particularly males over the age of 60, may
be similar to that of developing yellow fever. In contrast, in Africa,
the risk of acquiring yellow fever can be 600 times, and of death
700 times, the risk of vaccination.
An  understanding of the makeup of the ﬂavivirus genome is
helpful in understanding the new vaccines being developed based
upon the yellow fever vaccine virus as a vector. Flaviviruses are
single stranded, positive sense RNA viruses. Their genomes encode
three structural genes (capsid [C], pre-membrane [prM], envelope
[E]) and at least seven non-structural genes (NS1, NS2a, NS2b,
Open access under CC BY-NC-ND license.NS3, NS4a, NS4b, and NS5) in that order [24]. The coding region
is ﬂanked by non-coding regions at the 5′ and 3′ ends of the
genome. The YF 17D vaccine was  developed by serial passage of a
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Table  1
Risk/beneﬁt assessment for live virus vaccines based on a yellow fever vaccine backbone.
1. Basic information Information
1.1. Author(s) Thomas P. Monath MD/modiﬁed by Stephen J. Seligman MD/moderated by Jim S. Robertson MD
1.2.  Date
completed/updated
March  1, 2011 (JSR), updated September 25, 2014 (SJS,TPM)
2.  Vaccine vector
information
Information
2.1. Name of vaccines Yellow fever 17D-204, Yellow fever 17DD, ChimeriVax-TDV (CYD-TDV), ChimeriVax-JE, Imojev®, ChimeriVax WN
2.2. Class/subtype Flaviviridae/Flavivirus single strand positive-sense RNA virus
2.3.  Proposed route of
administration
Subcutaneously
3.  Characteristics of wild
type agent and
attenuated vaccine
derived  from them
Information Comments/concerns Reference(s)
3.1. Disease(s) caused by
wild type, the strength of
evidence, severity, and
duration  of disease for
the following categories:
Wild-type yellow fever (YF) virus causes hepatitis
and hemorrhagic fever
Mortality rates of 20–50% [15]
3.1a.  Disease(s) caused by
attenuated live yellow
fever  virus vaccine
Overall  Yellow fever vaccine associated neurotropic
(YEL-AND) and viscerotropic (YEL-AVD) serious
adverse effects
Reporting  rate of YEL-AND is 0.8 per 100,000
overall. According to VAERS data, reporting rate of
YEL-AVD is 0.4 per 100,000 overall. Other
estimates vary widely. Risk for YEL-AVD increases
in males with age ≥ 56. In 2001, a series of reports
appeared in Lancet describing severe, frequently
fatal, viscerotropic reactions to yellow fever
vaccine that stimulated surveillance of what had
been  considered the safest of live virus vaccines.
Additional cases of YEL-AVD in prospective
travelers and in inhabitants of South America were
recognized. In S. America the incidence may  be
underestimated because much of the vaccine is
administered to previously vaccinated individuals.
In Peru the incidence of fatal reactions in a
previously unimmunized population approached 1
in  10,000. In Africa surveillance for AEFI remains
inadequate, although WHO  has conducted
follow-up for adverse events after mass YF vaccine
campaigns, without deﬁnitive identiﬁcation of
YEL-AVD
[17–20,27–30]
In  immunocompromized Association of thymic disease with YEL-AVD.
Immune deﬁciency a contraindication to YF 17D.
Systemic lupus erythematosus on corticosteroids
Thymic disease is a contraindication to YF 17D.
One report of YEL-AND (fatal) in a patient with
HIV/AIDS 3 fatal cases. No safety issues after
administration of YF17D in 102 HIV+ volunteers,
although rate of serious adverse events of up to 3%
cannot  be excluded
[22,29,31–33]
In  neonates, infants,
children
Age  < 6 months associated with risk of YEL-AND,
and is a contraindication. Children aged 6–9
months only vaccinated under special
circumstances and on the basis of current ofﬁcial
advice
[15,34]
During pregnancy and in
the unborn
Pregnancy  a hypothetical contraindication.
However congenital infections very rare and no
reports of adverse effects on fetus
Two  reports of neonates acquiring 17 D infection
and YEL-AND via milk from recently vaccinated
nursing mothers
[15,35]
Are  there any other
susceptible  populations
Elderly have higher risk of YEL-AND and elderly
males, YEL-AVD. Women  of prime childbearing age
Reporting  rate in persons >70 approx 2 per
100,000 for both YEL-AND and AVD
[20,21,27,36]
Animals  Wild-type YF causes similar disease in nonhuman
primates (NHP), and (adapted strains) in hamsters,
but is neurotropic (no hepatitis) in mice. YF 17D
vaccine inoculated IC neurotropic/lethal in mice
and  causes self-limited encephalitis in monkeys
YF  17D vaccine is controlled by monkey
neurovirulence test based on scoring inﬂammatory
lesions in brain/spinal cord
[15]
3.2.  Is there any known
evidence  of neurological
or  cardiac involvement
of  the wild type agent?
YEL-AND most often caused by neuroinvasion of
CNS  followed by acute meninogoencephalitis,
generally self-limited, rare sequelae. Rare except in
infants <6 mos. Wild-type YF does not cause
encephalitis (though the virus is neurovirulent in
mice  and monkeys after intracerebral inoculation).
Wild-type (Wt) virus and YEL-AVD associated with
myocarditis, but not a prominent feature
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Table  1 (Continued)
1. Basic information Information
3.3. What is known about the
types of human cells
infected  and the receptors
used  in humans and
animals?
In humans and NHP, wild-type YF infects multiple
types of lymphoid cells, including DCs and Kupffer
cells, then spreads to hepatocytes. YF 17D infects
skin at site of inoculation, regional nodes, then
reticulo-endothelial system (RES) and bone
marrow. Wt  dengue virus infects a large variety of
cell  types, including monocytes, macrophages, DCs
and  possibly endothelial cells. Chimeric YF/DEN
vaccines infect DCs in vitro
[37–39]
3.4. Does the agent replicate
in  the nucleus?
No
3.5.  What is the risk of
integration  into the human
genome?
None
3.6.  Does the agent establish
a  latent or persistent
infection?
Persistent YF 17D virus infection of experimentally
infected monkeys reported. No evidence in
wild-type yellow fever of humans, but not
speciﬁcally studied. One report of RNA genomes of
YF  17D in urine of humans approx. 6 mos. after
vaccination. Chronic infection with West Nile,
Japanese encephalitis, and TBE have been
described in animal models and in humans
IgM antibody lasting up to 18 months following 17D
vaccination in one study suggested the possibility of
persistent  infection
[40–43]
3.7.  How does the wild type
agent normally transmit?
By agency of blood feeding Aedes and Haemagogus
spp. mosquitoes
YF  17D vaccine incapable of infecting mosquitoes.
Recombinants produced by the insertion of dengue 4,
JE  and WN prM-E genes into wild-type YF showed a
signiﬁcant decrease in infectivity for mosquito vectors
compared to wild-type YF
[15,44–49]
3.8. What is known about the
mechanisms of immunity
to  the wild type agent?
Both wild-type and vaccine induced immunity
against future or repeated infection principally via
neutralizing antibodies. Innate immune responses
play an important role in early defense. CTLs
responsible for clearing infection and recovery
Defects in innate immunity (interferon pathways) may
underlie  susceptibility of rare individuals to severe
vaccine associated SAEs (YEL-AVD). Interferon receptor
k/o  mice develop viscerotropic disease
[50–52]
3.9.  Is there treatment
required  and readily
available  for the disease
caused  by the wild type
agent?
No. see cited review [53]
4.  Characteristics of proposed
chimeric vaccines
Information Comments/concerns Reference(s)
4.1.  What is the basis of
attenuation/inactivation?
Chimerization (replacement of structural
membrane and envelope genes (prM-E) with genes
from another ﬂavivirus). Evidence that
chimerization itself contributes to attenuation also
comes  from experiments showing that insertion of
prM-E  genes from wt DENV 4 in a wt YF Asibi
backbone results in decreased virulence. Multiple
mutations in the YF 17D non-structural genes that
occurred during empirical passage to develop the
attenuated 17D vaccine. In some vaccine
constructs, mutations were also inserted in the
prM-E genes of the gene donor virus to decrease
neurovirulence (WN  vaccine). For constructing the
chimeric JE vaccine, prM-E genes from the
attenuated SA1414.2 vaccine were used, already
containing some mutations as compared to wt JE
virus
[39,54–58]
4.2.  What is the risk of
reversion  to virulence or
recombination with wild
type  or other agents?
Negligible due to replacement of entire PrM-E
gene (chimerization), redundant mutations. See
discussion of recombination in reference cited
Attenuated YF 17D and 17DD vaccines differ from
wild-type YF in the genes encoding 20 amino acids. In
addition  there are 4 nT changes in the 3′UTR that also
might  affect attenuation. The prM-E sequences in the
YF  vaccine result in 8 amino acid changes. Accordingly,
the chimeric vaccines lack the mutations in the prM-E
genes  of 17D virus. Evaluation of chimeric vaccine
candidates versus parental YF 17D with respect to
markers  of attenuation in vitro and in vivo have
consistently shown that the chimeric viruses are more
attenuated than the parent. More than 29,000 humans
subjects have received ChimeriVax vaccines without
signiﬁcant safety issues. Empirical studies have been
performed to assess the biological consequences of
non-homologous recombination of the chimeric
vaccine viruses with prM-E or backbone sequences
from virulent ﬂaviviruses. These studies have shown
that  such recombinational events do not result in
restoration of a virulent phenotype or a virus that has
increased  potential to disseminate via mosquito bite
[44,56,59–63]
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Table  1 (Continued)
1. Basic information Information
4.3 Are yellow fever virus
and  chimeric viruses
derived  from them
genetically  stable?
YF  17D vaccine is an uncloned mixture (genetic
swarm) as shown for all other ﬂaviviruses. The 17D
vaccine contains multiple diverse plaque
populations and subpopulations of virions that
react with wild-type speciﬁc YF monoclonal
antibodies. In one fatal case of encephalitis caused
by  YF 17D vaccine, the virus isolated from brain
contained two  mutations that were associated
with increased neurovirulence. In contrast, 17D
isolates from cases of YEL-AVD have not shown
mutations or selection of a speciﬁc subpopulation
or variant associated with these adverse events.
Overall, sequencing studies show that yellow fever
17D  vaccines as manufactured using the seed lot
system, and the chimeric constructs derived from
them,  have demonstrated low rates of mutation
during in vitro and in vivo replication. Furthermore,
YF appears to be more genetically stable than other
RNA viruses. This may  be due in part to the high
ﬁdelity of its polymerase. However, 27% of the
yellow fever fusion peptide sequences deposited in
GenBank show changes in this highly conserved
region in contrast to 5% of other pathogenic
ﬂaviviruses suggesting that yellow fever virus is
not  more genetically stable than other ﬂaviviruses
at least in this small region
[64–72]
4.3a.  Are the chimeric
vaccine  candidates
genetically stable during
multiple  passages?
Yes  All chimeric vaccine candidates have been
assessed for genetic stability through serial
passages. YF polymerase appears to be quite stable
compared to other RNA viruses. ChimeriVax
vaccines have all been made by molecular cloning
and transfection of RNA into acceptable cell
substrates to produce vaccine seed. The resulting
seed stock is then biologically cloned (by plaque
puriﬁcation). Molecular and biological cloning
promote genetic homogeneity of the vaccine virus.
The  actual vaccines are passed only a few times in
cell  cultures during manufacture. They are
assessed for genetic stability on serial passage;
after these viruses accumulate a few mutations
related to adaptation to Vero cells, they have been
quite stable on serial passages. Quality control
procedures (sequencing) is used to monitor
genetic stability of virus seeds and vaccine lots.
Speciﬁcations for the consensus sequence are used
for  vaccine release
[39,57,68,70]
4.4. What is known about the
genetic stability during
in  vivo replication?
Less empirical information, but no indication of
instability, reversion to virulence
Serial in vivo passages in mice showed no reversion [69]
4.5.  Will a replication
competent agent be
formed?
The  chimeric vaccines are replication competent
4.6. What is the potential for
shedding and
transmission?
Considered unlikely, except for possible secretion
in breast milk. The presence of virus titers as high
as  6.2 × 109 genome equivalents/g in individuals
with YEL-AVD increases the possibility of
transmission
Chimeric YF/West Nile vaccine studied in horses;
no evidence for shedding but vaccines intended for
other  species may  need studies. Limited
persistence and bio-distribution in monkeys after
vaccination with Chimerivax-WN
[35,38,73,74]
4.7.  Will the agent survive in
the environment?
No
4.8. Is there a non-human
‘reservoir’?
Not  for the attenuated vaccine virus
4.9. Is there any evidence for
or against safety during
pregnancy?
See  discussion of YF17D vaccine
4.10. Can the vector
accommodate multigenic
inserts  or will several
vectors  be required for
multigenic  vaccines?
See  comments Tetravalent YF/dengue vaccine required making 4
separate  vectors and mixing in a formulation
[39,54]
4.11.  What is known about
the  effect of pre-existing
immunity  on ‘take’, safety
or  efﬁcacy in animal
models?
No  antivector immunity because prM-E
(containing neutralizing epitopes) of YF replaced
by corresponding genes of target vaccine virus.
Prior YF immunity does not interfere. T cell
responses to YF 17D non-structural proteins do not
preclude effective immunization or re-use of
vectors
Positive effect on chimeric dengue vaccine
immunogenicity due to prior 17D immunity
See  above reviews
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Table  1 (Continued)
1. Basic information Information
5. Manufacturing Information Comments/Concerns Reference(s)
5.1.  Describe the source (e.g.,
isolation, synthesis)
Infectious cDNA clone of YF 17D vaccine virus
Sanoﬁ Pasteur – Swiftwater PA
5.2.  Describe the provenance
of  the vector including
passage  history and
exposure  to animal
products
FDA licensed YF 17D vaccine No fetal bovine serum (FBS) or animal products
used in manufacturing process
5.3. Can the vector be
produced  in an acceptable
cell  substrate?
Yes Vero cells, WHO-87 cells, FDA bank deposited at
ATCC
5.4.  Describe the proposed
production  process
prM-E of vector replaced with corresponding
genes of virus against which immunity is desired
Chimeric RNA transfected into Vero cells to
produce chimeric live attenuated vaccine
See above reviews
5.5.  What are some
Purity/Potential
contaminants?
Virus puriﬁed from supernatant ﬂuid by depth
ﬁltration, ultraﬁltration, diaﬁltration
Is  there a large scale
manufacturing feasibility?
Vaccines already made at commercial scale
Are  there any IP issues and is
there free use of the
vector?
Proprietary, vector system is covered by multiple
patents
IP  licensed by Acambis from St Louis University and
NIH,  and multiple new patents ﬁled by Acambis.
Acambis acquired by sanoﬁ Pasteur in 2008
6.  Toxicology and potency
(Pharmacology)
Information Comments/Concerns Reference(s)
6.1.  What is known about the
replication, transmission
and  pathogenicity in
animals?
Multiple Good Laboratory Practice (GLP) toxicity
studies performed in nonhuman primates (NHP)
for  chimeric vaccines against Japanese
encephalitis, dengue, West Nile. The live chimeric
viruses replicate in mice, hamsters, monkeys,
cause transient viremia. Neurovirulence tests
performed in infant mice and NHP, using licensed
YF 17D vaccine as a reference control
In rodents and NHP, the chimeric vaccines were
signiﬁcantly less virulent than the licensed YF 17D
vaccine
[55,57,75–77]
6.2.  For replicating vectors,
has  a comparative
virulence and viral kinetic
study  been conducted in
permissive and susceptible
species?  (yes/no) If not,
what  species would be
used  for such a study? Is it
feasible to conduct such a
study?
Many such studies, see references See above[54]
6.3.  Does an animal model
relevant  to assess
attenuation exist?
Reduced viremia in NHP infected with
ChimeriVax-DEN versus Wt  DEN viruses. For the
encephalitides, e.g., JE and WN,  rodents and NHP
are  excellent models in which to assess
attenuation of neurovirulence. YF 17D is
neurovirulent (and in infant mice neuroinvasive),
whereas the chimeric vaccines are signiﬁcantly
attenuated. Speciﬁcations for release of seed
viruses include demonstration of reduced
neurovirulence in a GLP test in NHP
One of the difﬁculties in developing a dengue
vaccine has been the absence of a convenient
animal model. In nonhuman primates wild-type
dengue causes a transient viremia, but no disease.
A  mouse model for dengue has been described, but
since  it involves immunocompromized mice, it can
no  be used to evaluate vaccine efﬁcacy
See above [54,57,75,78]
6.4. Does an animal model
for  safety including
immuno-compromised
animals  exist?
Unpublished studies in hamsters treated with
cyclophosphamide showed no increase in
virulence except for prolonged subclinical viremia.
Chimeric JE vaccine was fully attenuated in type
I/II  IFN receptor KO mice (A129 or AG129)
[57,79]
6.5.  Does an animal model
for  reproductive toxicity
exist?
Yes, but not tested Ongoing for chimeric dengue vaccine
6.6.  Does an animal model
for  immunogenicity and
efﬁcacy  exists?
Hamsters, mice, horses, monkeys See references and reviews [80]
6.7.  What is known about
biodistribution?
Replicates in skin at site of inoculation, then
draining nodes, then RES and bone marrow
Virus cleared after adaptive immunity established [38]
6.8.  Have neurovirulence
studies  been conducted?
Multiple All lots of vaccine tested by sensitive
neurovirulence test in infant mice. GLP
neurovirulence studies in NHP for all new vaccine
constructs, using licensed YF 17D as reference
control
[75]
6.9.  What is the evidence
that  the vaccines will
generate  a beneﬁcial
immune  response in
Rodent?  Rodents (mice, hamsters) immunized with single
inoculation develop neutralizing antibodies and
protected against challenge with wild-type virus
corresponding to the inserted prM-E gene
Examples include Japanese encephalitis and West
Nile
See  above [54,57]
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Table  1 (Continued)
1. Basic information Information
Non rodent? Horses immunized and protected against West Nile Licensed vaccine (Prevenile®, Intervet) for horses [77,79,81–84]
NHP?  Multiple studies showing immunogenicity and
protection against challenge with dengue, JE, WN
[54,77,81,83]
Human?  The ChimeriVax-JE vaccine (Imojev®) was
approved in Australia, Thailand and other Asian
countries based on Phase 1–3 studies showing
non-inferiority of neutralizing antibody responses
to  approved JE vaccine. The ChimeriVax-WN
vaccine has been shown to elicit protective levels
of  neutralizing antibodies as well as strong T cell
responses in Phase 1–2 clinical trials. A
placebo-controlled phase 2b study of tetravalent
ChimeriVax-DEN in Thai children conducted in a
single  site demonstrated protection against types
1,  3 and 4 but, despite the production of
neutralizing antibodies, there was  no observed
protection from disease with type 2 dengue, the
most  prevalent circulating serotype. A subsequent
phase 3 study in Asian children conducted in 5
countries and 11 sites found 56% overall protection
against dengue fever (which met  the proscribed
study end-point), however efﬁcacy against dengue
2  was lower than for other serotype. 35%
protection against type 2 dengue was observed,
compared to 50 to 78% protection against the other
serotypes. Vaccine efﬁcacy of against dengue
hemorrhagic fever (DHF) was  88.5% (per protocol)
and 67.2% against hospitalization (intent to treat).
A  phase 3 study in Latin America further conﬁrmed
the results obtained in Asia, with a 61% overall
protection against dengue fever, with an efﬁcacy of
50%  against serotype 1, 42% against serotype 2, 74%
against serotype 3 and 77% against serotype 4. A
signiﬁcant protection was also observed against
severe disease and hospitalization. Multiple
previous Phase 2 studies also suggested a similar
level of efﬁcacy
The  Thai study of ChimeriVax-DEN with
conﬁrmation from an Asian and Latin American
study, raises the possibility that protective efﬁcacy
is  lower against type 2 dengue. However,
protection against hospitalization and severe
dengue involved all 4 serotypes. In the phase 3
studies there were no deaths caused by dengue in
the  control or vaccine groups. Accordingly the
efﬁcacy of the vaccine in preventing mortality
remains to be studied
[38,39,45,57,85–89]
Sanoﬁ  Pasteur,
unpublished data, [90]
6.10. Have challenge or
efﬁcacy  studies been
conducted  with
HIV?  See 3.1a in immunocompromized
Other diseases? JE, dengue, WN (see refs)
7. Previous human use Please type one of the following: yes, no,
Unknown, N/A (non-applicable)
Comments  Reference(s)
7.1.  Has the vector already
been  used for targeting the
disease of vector origin
(measles,  BCG, rabies)?
Yes, licensed vaccine against YF
7.2.  What is known about the
replication, transmission
and  pathogenicity of the
vector  in:
See ﬁrst section
healthy people?
Immunocompromised?
neonates, infants,
children?
pregnancy and in the
unborn?
gene  therapy experiments?
any other susceptible
populations?
7.3.  Is there any previous
human  experience with a
similar vector including in
HIV+ (safety and
immunogenicity records)?
non-applicable
7.4.  Is there any previous
human  experience with
present  vector including
HIV+  (safety and
immunogenicity records)?
see 3.1a
7.5. What is known about the
effect of pre-existing
immunity on ‘take’, safety
or  efﬁcacy in any human
studies  with this or
different  insert?
prior administration of 17D does not interfere with
the  chimeric vaccines
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Table  1 (Continued)
1. Basic information Information
7.6. Name some other
non-HIV  vaccines using
same vector and describe
some  of the public health
considerations.
none
8. Overall Risk Assessment Describe the toxicities Please rate the risk as one of the following: none,
minimal, low, moderate, high, or unknown
Comments Reference(s)
8.1. What is the potential for
causing serious unwanted
effects  and toxicities in:
Healthy  people? Multiple trials of chimeric YF with JE, dengue, WN
gene  inserts have not shown any signiﬁcant safety
issues
The chimeric JE vaccine (ImoJev®) is licensed, the
chimeric dengue vaccine is in Phase III and the WN
vaccine is in Phase II. A veterinary vaccine against
WN  is licensed
See previous
and [91]
Immunocompromised? No data
Neonates, infants,
children?
Trials of the chimeric JE and dengue vaccines have
been  conducted in children 2 years and older, and
have  shown them to be safe and well tolerated.
Pregnancy  and in the
unborn?
No data. Parental YF 17D (and therefore
ChimeriVax) not be administered during
pregnancy unless clearly required, based on a high
risk  exists of natural infection
Other susceptible
populations?
8.2.  What is the risk of neu-
rotoxicity/neuroinvasion
or cardiac effects?
The vaccines are signiﬁcantly less neurovirulent
than the licensed YF 17D vaccine
[75]
8.3.  What is the potential for
shedding and transmission
in  risk groups?
YF 17D rarely transmitted to infants via breast milk
Viremia titers as high as 6.2 × 109 genome
equivalents/g in individuals dying with YEL-AVD
raise the possibility of transmission by blood but
likelihood of adverse event low since the virus in
such  individuals has few/no mutations
However, multiple studies have shown that the
chimeric vaccines are not infectious for mosquitoes
[45–49,74]
8.4. What is the risk of
adventitious  agent
(including  TSE)
contamination?
Minimal. Seed viruses and each vaccine lot are
tested for adventitious viruses. No animal products
used in manufacturing.
8.5. Can the vector be
manufactured  at scale in
an acceptable process?
Yes, the JE vaccine is at commercial scale now;
Sanoﬁ Pasteur has constructed a commercial
factory for the dengue vaccine
10,000–50,000 doses per L–very efﬁcient process
8.6.  Can virulence,
attenuation and toxicity be
adequately assessed in
preclinical  models?
Yes
8.7.  Rate the evidence that a
beneﬁcial response will be
obtained in humans.
Already known—neutralizing antibodies in >95% of
human  subjects. T cell responses to the E protein
conserved in humans
The  dengue vaccine contains a mixture of 4
separate viruses each representing 1 serotype.
Interference between the individual viruses is
observed, so that 2-3 doses are required for
complete immunization. In contrast the JE and WN
vaccines are monovalent and a single dose
provides durable immunity and T cell memory. The
proposed correlate of protection for chimeric
vaccines against encephalitic viruses (JE, WN)  is
the  level of neutralizing antibodies (PRNT50 titer),
and  a level of >10 is considered protective; the
chimeric vaccines elicit neutralizing antibody
titers in great excess over this minimum protective
level. However, an immune correlate is not
established yet for dengue vaccines. Cellular
immunity may  also contribute to protection, and it
has  been shown that chimeric vaccines are able to
induce  signiﬁcant responses in this respect.
[39,57,91–93]
9. Adverse Effect Assessment Describe the adverse effects Please rate the risk as one of the following: none,
minimal, low, moderate, high, or unknown
Comments Reference(s)
9.1. Describe the adverse
effects  observed
Mild  local reactions Erythema, pain Minimal
Mild systematic reactions Similar to placebo
Moderate local reactions Erythema, pain Minimal
Moderate systematic
reactions
Similar to placebo
Severe local reactions None
Severe systematic
reactions
None
10.  Administration
Assessment
Information Comments/Concerns Reference(s)
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Table  1 (Continued)
1. Basic information Information
10.1. What is the average
Tissue  Culture Infections
Dose  per millimeter
(TCID/ml)?
Human dose is 3-5 log10 plaque forming units
(PFU).
10.2.  What is the highest
TCID/ml  that can be used
before  cell toxicity?
The viruses cause CPE in vitro at low multiplicities
of infection (MOI).
10.3. Are different
demographics affected
No information
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References 
ild-type virus in chicken embryo cultures resulting in the acqui-
ition of nucleotide mutations some of which do not cause changes
n the translated amino acids (synonymous) and some of which
o (non-synonymous). In the YF-17D vectored vaccines that are
eing developed for Japanese encephalitis, West Nile and the four
erotypes of dengue viruses, the coding regions of the prM-E pro-
eins of the corresponding viruses are substituted for those in the
F 17D virus vaccine, resulting in a chimeric virus. The YF-17D
iral genome excluding the prM-E genes is referred to as the “back-
one”. Although the production of such chimeric viruses alone may
ecrease their virulence, preclinical studies have demonstrated
hat the YF backbone has sufﬁcient mutations by itself to main-
ain vaccine attenuation of chimeric vaccines bearing the dengue
urface antigens [22]. Another aspect of the chimeric ﬂavivirus
echnology that is distinguished from other viral vectors, is that
nti-vector immunity is not a signiﬁcant problem for ﬂavivirus
accine development. This feature is due to the fact that the prM-
 region is solely responsible for generating epitopes recognized
y neutralizing antibodies. Thus, the chimeric vector contains the
nly neutralizing antigens of the intended target for immunization.
revious immunization with YF17D and T cell responses to the YF
7D backbone are insufﬁcient to prevent effective immunization
ith a chimeric vector expressing a heterologous ﬂavivirus prM-E
ransgene.
The efforts of the V3SWG were focused initially on the above ﬂa-
ivirus vaccines. Not addressed are additional possible vaccines in
hich nucleotide sequences encoding for epitopes of other micro-
rganisms might be added into the complete YF virus vaccine
ielding live virus vaccines with additional vaccination poten-
ial. Vaccines employing other methods of attenuating ﬂaviviruses
hrough mechanisms such as nucleotide deletions and which do
ot involve a viral vector are not considered in this project [25].
The  chimeric vaccines indicated for the prevention of dengue,
apanese encephalitis, and West Nile will be considered new
ntities from the regulatory perspective, and will need to be
ndependently assessed for safety and efﬁcacy. However, in the
evelopment of these new vaccines, the parental YF 17D vac-
ine virus has provided an important comparator and benchmark
n all preclinical and many clinical trials. For example, the mon-
ey neurovirulence test is an important measure of safety of YF
7D vaccines, and YF 17D was used as the reference strain in
any studies, which showed that the chimeric vaccines were
ore attenuated than parental YF 17D. An important regulatory
uestion thus arises as to whether the age range for vaccina-
ion, precautions and contraindications in labelling for use of YF
7D vaccines should apply to the new, chimeric vaccines. This
uestion is particularly important since data on very rare adverse
vents will likely not be available at the time the new vaccines are
pproved. The template supplied in this paper contains informa-
ion that can potentially be useful in considering how new chimeric
accines should be described in reference to parental YF 17D
accines.Information
1.3.  Methods for developing, completing and reviewing the
standardized template
Following  the process described in the accompanying overview
paper [26] as well as on the Brighton Collaboration website
(http://cms.brightoncollaboration.org:8080/public/what-we-do/
setting-standards/case-deﬁnitions/process.html), the Brighton
Collaboration V3SWG was formed in October 2008 and includes
∼15 members with clinical, academic, public health, regulatory
and industry backgrounds with appropriate expertise and interest.
The composition of the working and reference group as well as
results of the web-based survey completed by the reference group
with subsequent discussions in the working group can be viewed at
http://www.brightoncollaboration.org/internet/en/index/working
groups.html. The workgroup meets via emails and monthly confer-
ence calls coordinated by a secretariat [currently at CDC’s Division
of HIV/AIDS Prevention].
The  V3SWG invited a ﬂavivirus expert, Thomas P. Monath (TPM),
who has been intimately associated with the development of ﬂa-
vivirus vaccines based on the YF virus vaccine backbone to complete
the template in 2011. The ﬁrst draft was then critiqued by a member
of the working group knowledgeable about ﬂaviviruses, Stephen J.
Seligman (SJS), moderated by another member, James S. Robertson
(JSR), discussed by the V3SWG as a whole, and then peer reviewed
by reference groups (e.g., American Society of Virology, American
Society of Tropical Medicine and Hygiene) and the Brighton Collab-
oration membership. Bruno Guy updated the template with new
information as of October, 2014. Sections 8 (overall risk assess-
ment) and 9 (adverse effect assessment) of the template seeks to
rate the risk of the viral vector in various situations as: none, min-
imal, low, moderate, high, or unknown. An initial assessment was
made by TPM and then reviewed by others, based largely on the
anticipated frequency and severity of the vaccine adverse event
versus the expected frequency and severity of the target vaccine
preventable disease [15]. Depending on the season, the risk of the
yellow fever vaccine approaches the risk of YF in S. America. In
Africa the risk of yellow fever is usually much greater than the risk
of the vaccine. The V3SWG may  develop more explicit criteria for
standardizing the rating of these risks in the future with further
experience.
The resulting template is submitted as a guideline for evaluating
the current issues in development of vaccines based on the yellow
fever virus vaccine backbone.
2.  Standardized template (Table 1)
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